Dielectronic recombination of ground-state and metastable Li+ ions

Dielectronic recombination has been investigated for Delta n = 1 resonances of ground-state Li+(1s(2)) and for Delta n = 0 resonances of metastable Li (+) (1s2s S-3). The ground-state spectrum shows three prominent transitions between 53 and 64 eV, while the metastable spectrum exhibits many transitions with energies

Dielectronic recombination in Li+

Dielectronic recombination has been investigated for ground-state Li+(1s2s) and metastable Li+(1s2s) ions. Absolute recombination rates for the convoluted sum of these configurations are obtained and compared with theoretical calculations. Also, the effect of the space charge on the energy of the observed resonances is investigated as well as the effect of trapped residual, ions in reducing the effect of the space charge.

MEASUREMENT OF DIELECTRONIC RECOMBINATION IN HE+ IONS

Dielectronic recombination was investigated for He+, the simplest ion for which this process is possible. This work was done using the light-ion storage ring and electron cooler at the Indiana University Cyclotron Facility. Resonant recombination yields resulting from 1s +e- --> nln'l' transitions were observed with sufficient resolution (about 1 eV in the center of mass) to isolate and obtain cross sections for the 2s 2p 3P0 and 2p2 1D terms. The measured cross sections, integrated over the DELTAn = 1 2ln'l' states, agree in magnitude with theoretical calculations. Additionally, DELTAn = 2 dielectronic recombination events associated with 3ln'l' intermediate states were observed.

Detection of Voigt Spectral Line Profiles of Hydrogen Radio Recombination Lines toward Sagittarius B2(N)

We report the detection of Voigt spectral line profiles of radio recombination lines (RRLs) toward Sagittarius B2(N) with the 100 m Green Bank Telescope (GBT). At radio wavelengths, astronomical spectra are highly populated with RRLs, which serve as ideal probes of the physical conditions in molecular cloud complexes. An analysis of the Hn alpha lines presented herein shows that RRLs of higher principal quantum number (n > 90) are generally divergent from their expected Gaussian profiles and, moreover, are well described by their respective Voigt profiles. This is in agreement with the theory that spectral lines experience pressure broadening as a result of electron collisions at lower radio frequencies. Given the inherent technical difficulties regarding the detection and profiling of true RRL wing spans and shapes, it is crucial that the observing instrumentation produce flat baselines as well as high-sensitivity, high-resolution data. The GBT has demonstrated its capabilities regarding all of these aspects, and we believe that future observations of RRL emission via the GBT will be crucial toward advancing our knowledge of the larger-scale extended structures of ionized gas in the interstellar medium (ISM).

Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: Sensitivity to PARP inhibitors, platinum, and survival

Up to 50% of epithelial ovarian cancers (EOC) display defects in the homologous recombination (HR) pathway. We sought to determine the ramifications of the homologous recombination-deficient (HRD) status on the clinicopathologic features, chemotherapy response, and survival outcomes of patients with EOCs. HR status was determined in primary cultures from ascitic fluid in 50 chemotherapy-naïve patients by a functional RAD51 immunofluorescence assay and correlated with in vitro sensitivity to the PARP inhibitor (PARPi), rucaparib. All patients went on to receive platinum-based chemotherapy; platinum sensitivity, tumor progression, and overall survival were compared prospectively in HR-competent versus HRD patients. Compared with HR-competent patients, the HRD group was predominantly serous with a higher median CA125 at presentation. HRD was associated with higher ex vivo PARPi sensitivity and clinical platinum sensitivity. Median follow-up duration was 14 months; patients in the HRD group had lower tumor progression rates at 6 months, lower overall/disease-specific death rates at 12 months, and higher median survival. We therefore suggest that HRD as predicted by a functional RAD51 assay correlates with in vitro PARPi sensitivity, clinical platinum sensitivity, and improved survival outcome.